clinical trial · NCT00840606
Buspirone Hydrochloride 30mg Tablets, Fasting
Teva Pharmaceuticals USA·phase1·completed·n = 70
HealthyBUSPAR® 30 mg TabletBuspirone Hydrochloride 30 mg Tablet
brief summary
This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg BUSPAR® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 30 mg tablet) in healthy adult volunteers under fasting conditions.
started
Dec 1, 2001
primary completion
Dec 1, 2001
completion
Apr 1, 2002
last updated
Aug 19, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
A Relative Bioavailability Study of 30 mg Buspirone Hydrochloride Tablets Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol